307 related articles for article (PubMed ID: 33030312)
21. Planning for Outcomes (P
Lebetkin E; Gao X; Taylor D; Maldonado LY; Saad A; Steiner MJ; Dorflinger LJ; Nanda K; Mastro TD
Glob Health Sci Pract; 2019 Jun; 7(2):317-328. PubMed ID: 31189699
[TBL] [Abstract][Full Text] [Related]
22. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
Singata-Madliki M; Smit J; Beksinska M; Balakrishna Y; Avenant C; Beesham I; Seocharan I; Batting J; Hapgood JP; Hofmeyr GJ
PLoS One; 2024; 19(3):e0295764. PubMed ID: 38530848
[TBL] [Abstract][Full Text] [Related]
23. Hormonal contraception and the risk of HIV acquisition among women in South Africa.
Morrison CS; Skoler-Karpoff S; Kwok C; Chen PL; van de Wijgert J; Gehret-Plagianos M; Patel S; Ahmed K; Ramjee G; Friedland B; Lahteenmaki P
AIDS; 2012 Feb; 26(4):497-504. PubMed ID: 22156973
[TBL] [Abstract][Full Text] [Related]
24. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.
Crook AM; Ford D; Gafos M; Hayes R; Kamali A; Kapiga S; Nunn A; Chisembele M; Ramjee G; Rees H; McCormack S
Hum Reprod; 2014 Aug; 29(8):1810-7. PubMed ID: 24838704
[TBL] [Abstract][Full Text] [Related]
25. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
Kaunitz AM
J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
[TBL] [Abstract][Full Text] [Related]
26. Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate.
Haddad LB; Cwiak C; Jamieson DJ; Feldacker C; Tweya H; Hosseinipour M; Hoffman I; Bryant AG; Stuart GS; Noah I; Mulundila L; Samala B; Mayne P; Phiri S
Contraception; 2013 Dec; 88(6):737-43. PubMed ID: 24060297
[TBL] [Abstract][Full Text] [Related]
27. Increased Cervical CD4
Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
[TBL] [Abstract][Full Text] [Related]
28. Association of endogenous progesterone levels in young women using hormonal contraception with recent HIV-1 infection.
Boodhram R; Moodley D; Abbai N; Ramjee G
BMC Womens Health; 2019 May; 19(1):63. PubMed ID: 31068152
[TBL] [Abstract][Full Text] [Related]
29. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa.
Myer L; Denny L; Wright TC; Kuhn L
Int J Epidemiol; 2007 Feb; 36(1):166-74. PubMed ID: 17175547
[TBL] [Abstract][Full Text] [Related]
31. Risk of HIV-1 acquisition among South African women using a variety of contraceptive methods in a prospective study.
Palanee-Phillips T; Brown ER; Szydlo D; Matovu Kiweewa F; Pather A; Harkoo I; Nair G; Soto-Torres L; Hillier SL; Baeten JM;
AIDS; 2019 Aug; 33(10):1619-1622. PubMed ID: 31306167
[TBL] [Abstract][Full Text] [Related]
32. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
[TBL] [Abstract][Full Text] [Related]
33. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.
Polis CB; Phillips SJ; Curtis KM; Westreich DJ; Steyn PS; Raymond E; Hannaford P; Turner AN
Contraception; 2014 Oct; 90(4):360-90. PubMed ID: 25183264
[TBL] [Abstract][Full Text] [Related]
34. Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial.
Akello CA; Bunge KE; Nakabiito C; Mirembe BG; Fowler MG; Mishra A; Marrazzo J; Chirenje ZM; Celum C; Balkus JE
J Womens Health (Larchmt); 2017 Jun; 26(6):670-676. PubMed ID: 28437215
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Female Genital Tract Cytokine and Microbiota Signatures Induced by Initiation of Intramuscular DMPA and NET-EN Hormonal Contraceptives - a Prospective Cohort Analysis.
Dabee S; Tanko RF; Brown BP; Bunjun R; Balle C; Feng C; Konstantinus IN; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Gill K; Baeten JM; Bekker LG; Passmore JS; Heffron R; Jaspan HB; Happel AU
Front Immunol; 2021; 12():760504. PubMed ID: 34956191
[TBL] [Abstract][Full Text] [Related]
36. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
Mugo NR; Stalter RM; Heffron R; Rees H; Scoville CW; Morrison C; Kourtis AP; Bukusi E; Beksinka M; Philip NM; Beesham I; Deese J; Edward V; Donnell D; Baeten JM;
Clin Infect Dis; 2022 Sep; 75(4):586-595. PubMed ID: 34910143
[TBL] [Abstract][Full Text] [Related]
37. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
Liu J; Shen J; Diamond-Smith N
Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
[TBL] [Abstract][Full Text] [Related]
39. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
[TBL] [Abstract][Full Text] [Related]
40. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
